GreenLight Biosciences Holdings, PBC Common Stock
GRNA
GRNA was delisted on the 21st of July, 2023.
39 hedge funds and large institutions have $280M invested in GreenLight Biosciences Holdings, PBC Common Stock in 2022 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 57 closing their positions.
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
61% more capital invested
Capital invested by funds: $173M → $280M (+$106M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
43% less funds holding
Funds holding: 68 → 39 (-29)
51% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 57
60.37% less ownership
Funds ownership: 84.37% → 24% (-60%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$60.1M |
| 2 |
VS
VK Services
Menlo Park,
California
|
+$46.8M |
| 3 |
CGC
Continental Grain Company
New York
|
+$44.4M |
| 4 |
TCM
Tao Capital Management
San Francisco,
California
|
+$23.9M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$18.9M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
-$10.6M |
| 3 |
KC
Kryger Capital
London,
United Kingdom
|
-$8.86M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$7.8M |
| 5 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$7.67M |
GRNA Hedge Fund Activity: Q1 2022 in Review
39 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in GreenLight Biosciences Holdings, PBC Common Stock (GRNA) for Q1 2022, worth a combined $280M — up 61% from $173M a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of GRNA and 28 opened new positions — a net loss of 29 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $60.1M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $18.9M sold.
- 39 institutional investors held GreenLight Biosciences Holdings, PBC Common Stock (GRNA) as of Q1 2022, down from 68 in Q4 2021.
- Funds reported $280M of GreenLight Biosciences Holdings, PBC Common Stock stock for Q1 2022, up 61% quarter-over-quarter.
- 28 funds opened new GreenLight Biosciences Holdings, PBC Common Stock positions in Q1 2022 and 57 closed out, a net change of -29 holders.
- The largest GreenLight Biosciences Holdings, PBC Common Stock buyer in Q1 2022 was Cormorant Asset Management, an estimated $60.1M added.
- The largest GreenLight Biosciences Holdings, PBC Common Stock seller in Q1 2022 was Highbridge Capital Management, an estimated $18.9M sold.
Based on aggregated 13F filings for Q1 2022.